Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Rheumatol. 2007 May;19(3):308-13.

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.

Author information

  • 1Wolters Kluwer Health /Adis, Auckland, New Zealand. demail@adis.co.nz

Abstract

(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis.(2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab.(3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk